amlodipine has been researched along with Death, Sudden, Cardiac in 9 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, we aimed to compare the effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese elderly patients with high-risk hypertension and to determine their optimal target blood pressures (BPs)." | 7.74 | The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Fukiyama, K; Fukui, T; Matsuoka, H; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Shimamoto, K; Ueshima, K, 2008) |
| "Amlodipine treatment resulted in a greater relative reduction in sudden deaths (21%) than in pump failure deaths (6." | 6.69 | Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. ( Anderson, S; Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, DJ; Miller, AB; Neuberg, GW; O'Connor, CM; Pressler, ML; Wertheimer, JH, 1998) |
| " In this sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, we aimed to compare the effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese elderly patients with high-risk hypertension and to determine their optimal target blood pressures (BPs)." | 3.74 | The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Fukiyama, K; Fukui, T; Matsuoka, H; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Shimamoto, K; Ueshima, K, 2008) |
| "The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure." | 2.78 | Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013) |
| "The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown." | 2.74 | Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). ( Abbate, A; Erne, P; Jamshidi, P; Kobza, R; Pfisterer, M; Schoenenberger, AW; Stuck, AE; Zuber, M, 2009) |
| "Amlodipine treatment resulted in a greater relative reduction in sudden deaths (21%) than in pump failure deaths (6." | 2.69 | Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. ( Anderson, S; Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, DJ; Miller, AB; Neuberg, GW; O'Connor, CM; Pressler, ML; Wertheimer, JH, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, P | 1 |
| Yau, C | 1 |
| Kurian, J | 1 |
| Yamashita, K | 1 |
| Kondo, T | 1 |
| Muramatsu, T | 1 |
| Matsushita, K | 1 |
| Nagahiro, T | 1 |
| Maeda, K | 1 |
| Shintani, S | 1 |
| Murohara, T | 1 |
| Ogihara, T | 1 |
| Nakao, K | 1 |
| Fukui, T | 2 |
| Fukiyama, K | 1 |
| Fujimoto, A | 1 |
| Ueshima, K | 1 |
| Oba, K | 1 |
| Shimamoto, K | 1 |
| Matsuoka, H | 1 |
| Saruta, T | 1 |
| Schoenenberger, AW | 2 |
| Kobza, R | 1 |
| Jamshidi, P | 1 |
| Zuber, M | 2 |
| Abbate, A | 1 |
| Stuck, AE | 1 |
| Pfisterer, M | 2 |
| Erne, P | 2 |
| Rahn, KH | 1 |
| Burckhardt, D | 1 |
| Kiowski, W | 1 |
| Dubach, P | 1 |
| Resink, T | 1 |
| O'Connor, CM | 2 |
| Carson, PE | 1 |
| Miller, AB | 2 |
| Pressler, ML | 1 |
| Belkin, RN | 1 |
| Neuberg, GW | 2 |
| Frid, DJ | 1 |
| Cropp, AB | 1 |
| Anderson, S | 2 |
| Wertheimer, JH | 2 |
| DeMets, DL | 1 |
| Carson, PA | 1 |
| Belkin, R | 1 |
| Frid, D | 1 |
| Cropp, A | 1 |
| Packer, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amlodipine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
[CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
5 trials available for amlodipine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sud | 2013 |
Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Antihypertensi | 2009 |
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su | 2007 |
Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation.
Topics: Amlodipine; Calcium Channel Blockers; Cause of Death; Death, Sudden; Death, Sudden, Cardiac; Double- | 1998 |
Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Circadian Rhythm; Death, Sudde | 2000 |
2 other studies available for amlodipine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
ST elevation myocardial infarction after coronary artery spasm with no clear trigger.
Topics: Amlodipine; Arrhythmias, Cardiac; Cardiopulmonary Resuscitation; Coronary Angiography; Coronary Vaso | 2017 |
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl | 2008 |